Top

World Journal of Surgical Oncology

Published in:

Open Access 01-12-2019 | Melanoma | Research

Comparison of seventh and eighth edition of AJCC staging system in melanomas at locoregional stage

Authors: Pawel Teterycz, Iwona Ługowska, Hanna Koseła-Paterczyk, Piotr Rutkowski

Published in: World Journal of Surgical Oncology | Issue 1/2019

Abstract

Background

The eighth edition of the American Joint Committee on Cancer (AJCC) staging system has been effective since January 2018. It has introduced some major changes in the localized/locoregional melanoma classification. However, it has not been demonstrated how this classification was validated on external, clinical data.

Patients and methods

In this retrospective study, we have included 2474 patients diagnosed with cutaneous melanoma in localized or locoregional stage. They were treated surgically in our Center between years 1998 and 2014. Melanoma-specific and overall survival were calculated for each stage according to TNM7 and TNM8 using Kaplan-Meier estimator.

Results

The melanoma-specific survival rates in our patients were similar to those reported from original cohort used to build TNM8 classification except for stage IIIC (5-year melanoma-specific survival 44.6% vs 51.8%, respectively for TNM7 vs TNM8).

Conclusion

Our study validated the eighth edition of TNM melanoma staging system as a viable tool in prognosis of the long-term survival of patients with localized or locoregionally advanced melanoma on an independent cohort. The new TNM 8 system has brought important improvements in prognostic assessment for melanoma patients. Deeper understanding of the significance of satellite/in-transit lesions may be required.

Available only for authorised users

Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol. 2003;4:748–59.CrossRefPubMed

Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019. https://doi.org/10.1056/NEJMoa1904059.

Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Cowey CL, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:1480–92. https://doi.org/10.1016/S1470-2045(18)30700-9.CrossRefPubMed

Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Eng J Med 2017;0:null. doi:https://doi.org/10.1056/NEJMoa1709030.CrossRefPubMed

Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandalà M, et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma. J Clin Oncol. 2018:JCO1801219. https://doi.org/10.1200/JCO.18.01219.CrossRefPubMedPubMedCentral

Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:472–92. https://doi.org/10.3322/caac.21409.CrossRefPubMedPubMedCentral

Rutkowski P, Szydłowski K, Nowecki ZI, Sałamacha M, Goryń T, Mitręga-Korab B, et al. The long-term results and prognostic significance of cutaneous melanoma surgery using sentinel node biopsy with triple technique. World J Surg Oncol. 2015;13:299. https://doi.org/10.1186/s12957-015-0701-8.CrossRefPubMedPubMedCentral

Team RC. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2017.

Wickham H. tidyverse: easily install and load “Tidyverse” packages. 2017.

10.

Kassambara A, Kosinski M. survminer: drawing survival curves using “ggplot2.” 2018.

11.

Gershenwald JE, Scolyer RA. Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond. Ann Surg Oncol. 2018;25:2105–10. https://doi.org/10.1245/s10434-018-6513-7.CrossRefPubMed

12.

Grob JJ, Schadendorf D, Lorigan P, Ascierto P, Larkin J, Nathan P, et al. Eighth American Joint Committee on Cancer (AJCC) melanoma classification: let us reconsider stage III. Eur J Cancer. 2018;91:168–70. https://doi.org/10.1016/j.ejca.2017.11.023.CrossRefPubMed

13.

Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. New England Journal of Medicine. 2017;376:2211–22. https://doi.org/10.1056/NEJMoa1613210.CrossRefPubMed

14.

Verver D, van Klaveren D, van Akkooi ACJ, Rutkowski P, Powell BWEM, Robert C, et al. Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations. Eur J Cancer. 2018;96:25–33. https://doi.org/10.1016/j.ejca.2018.02.022.CrossRefPubMed

15.

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, et al. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. Eur J Cancer. 2019;116:148–57. https://doi.org/10.1016/j.ejca.2019.05.020.CrossRefPubMed

16.

Verver D, Louwman WJ, Koljenović S, Verhoef C, Grünhagen DJ, van Akkooi ACJ. Improved stratification of pT1 melanoma according to the 8th American Joint Committee on Cancer staging edition criteria: a Dutch population-based study. Eur J Cancer. 2018;92:100–7. https://doi.org/10.1016/j.ejca.2017.10.031.CrossRefPubMed

17.

Crocetti E, Stanganelli I, Mancini S, Vattiato R, Giuliani O, Ravaioli A, et al. Evaluation of the agreement between TNM 7th and 8th in a population-based series of cutaneous melanoma. J Eur Acad Dermatol Venereol. 2018. https://doi.org/10.1111/jdv.15285.CrossRefPubMed

18.

Tarhini A, Ghate S, Ionescu-Ittu R, Shi S, Nakasato A, Ndife B, et al. Stage III melanoma incidence and impact of transitioning to the 8th AJCC staging system: a US population-based study. Future Oncol. 2018. https://doi.org/10.2217/fon-2018-0671.CrossRefPubMed

19.

Isaksson K, Katsarelias D, Mikiver R, Carneiro A, Ny L, Olofsson Bagge R. A population-based comparison of the AJCC 7th and AJCC 8th editions for patients diagnosed with stage III cutaneous malignant melanoma in Sweden. Ann Surg Oncol. 2019. https://doi.org/10.1245/s10434-019-07448-y.

Title: Comparison of seventh and eighth edition of AJCC staging system in melanomas at locoregional stage
Authors: Pawel Teterycz
Iwona Ługowska
Hanna Koseła-Paterczyk
Piotr Rutkowski
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Melanoma
Melanoma
Published in: World Journal of Surgical Oncology / Issue 1/2019
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/s12957-019-1669-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Comparison of seventh and eighth edition of AJCC staging system in melanomas at locoregional stage

Abstract

Background

Patients and methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2019

Clinical silence of pulmonary lymphoepithelioma-like carcinoma with subcutaneous metastasis: a case report

Tumor budding for predicting prognosis of resected rectum cancer after neoadjuvant treatment

Is there a need for neoadjuvant short-course radiotherapy in T3 rectal cancer with positive lymph node involvement? A single-center retrospective cohort study

Perioperative chemotherapy versus neoadjuvant chemoradiation for patients with adenocarcinoma of the distal esophagus in Austria: a retrospective analysis

Breast cancer robotic nipple sparing mastectomy: evaluation of several surgical procedures and learning curve

Angiogenic inflammation and formation of necrosis in the tumor microenvironment influence patient survival after radical surgery for de novo hepatocellular carcinoma in non-cirrhosis